Overall, these results provide new molecular insights into immune-mediated LDD pathogenesis and highlight CDK1 and COL4A2 as potential biomarkers and therapeutic targets for precision diagnosis and treatment. This evidence concerns the gene COL4A2 and Lhermitte-Duclos disease.